Details for New Drug Application (NDA): 202551
✉ Email this page to a colleague
The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for 202551
| Tradename: | SOLIFENACIN SUCCINATE |
| Applicant: | Watson Labs Inc |
| Ingredient: | solifenacin succinate |
| Patents: | 0 |
Pharmacology for NDA: 202551
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Medical Subject Heading (MeSH) Categories for 202551
Suppliers and Packaging for NDA: 202551
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 202551 | ANDA | Actavis Pharma, Inc. | 0591-3795 | 0591-3795-19 | 90 TABLET, FILM COATED in 1 BOTTLE (0591-3795-19) |
| SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 202551 | ANDA | Actavis Pharma, Inc. | 0591-3795 | 0591-3795-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0591-3795-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | May 20, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | May 20, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
